Tags:IT
With a passion to help patients defeat their cancer, Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. On March 2nd, 2020, Gilead announced it will acquire Forty Seven for $4.9 billion.
Total raised: $156M

Investors 2

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
07.08.2019-$6M-finsmes.co...
18.10.2017Series B$75M-finsmes.co...
25.02.2016Series A$75M-fiercebiot...

Mentions in press and media 20

DateTitleDescriptionCategoryAuthorSource
21.03.2020Gilead To ...Gilead Sciences, Inc. (Nasdaq:...USA-finsmes.co...
02.03.2020Gilead to ...Forty Seven’s lead product can...--medcitynew...
12.02.2020ALX Oncolo...The company plans to invest th...--medcitynew...
07.08.2019Forty Seve...Forty Seven, Inc., a Menlo Par...USA-finsmes.co...
26.03.2019Arch Oncol...The financing was led by a new...--medcitynew...
28.06.2018Term Sheet...LYFTED Good morning, Term She...--fortune.co...
19.06.2018Term Sheet...MORE DATA, FEWER HUMANS What’...--fortune.co...
20.10.2017Term Sheet...TRENDY IPO Happy Friday, Term...--fortune.co...
18.10.2017Forty Seve...Forty Seven has raised $75 mil...Biotech-fiercebiot...
18.10.2017Forty Seve... MENLO PARK, CA, Clinical-sta...--vcnewsdail...
Show more